MEI Pharma, Inc. 是一家從事藥品化合物開發的製藥公司。公司總部位於美國加州聖地牙哥,目前聘有28名全職員工。該公司在2003年12月18日上市。該公司的資金計畫以萊特幣為基礎。公司已終止voruciclib的臨床開發,但與其候選藥物資產相關的某些非臨床活動仍在繼續進行。作為戰略選擇評估的一部分,公司可能會考慮現有項目的外部授權機會以及合併與收購機會。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for LITS. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: LITS is a Sell candidate.
LITS stock price ended at $1.14 on 星期三, after dropping 1.72%
On the latest trading day Apr 01, 2026, the stock price of LITS fell by 1.72%, dropping from $1.16 to $1.14. During the session, the stock saw a volatility of 6.19%, with prices oscillating between a daily low of $1.13 and a high of $1.20. On the latest trading day, the trading volume for LITS decreased by 280.8K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 222.9K shares were traded, with a market value of approximately $41.4M.